Pre-application of arsenic trioxide may potentiate cytotoxic effects of vinorelbine/docetaxel on neuroblastoma SK-N-SH cells

Qi, Kai; Li, Yang; Huang, Ke; Xiong, Xi; Feng, Chuchu; Zhang, Chi; Weng, Wen-Jun

doi:10.1016/j.biopha.2019.108665

Cited by 18 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ATO was reported to induce arrest in the G1 or G2/M phases of the cell cycle in most solid tumor cells. Thus, the pre-application of ATO followed by VCR may potentiate anti-tumor effects, as demonstrated in our previous study in neuroblastoma cell lines (11). More specifically, the IC 50 of ATO on ARMS cell lines is 1.3-2.0 mM (9), which is very close to the effective serum concentration in the clinical treatment of acute promyelocytic leukemia (APL) (12).…”

Section: Introductionsupporting

confidence: 61%

Encouraging Early Outcomes of Treatment With Arsenic Trioxide Combined With Chemotherapy for Alveolar Rhabdomyosarcoma in Children: 4 Case Reports

et al. 2021

Self Cite

View full text Add to dashboard Cite

BackgroundAlveolar rhabdomyosarcoma (ARMS) is a subtype of rhabdomyosarcoma characterized by its aggressive behavior and poor prognosis, highlighting the need for novel treatment options. Arsenic trioxide (ATO) has been shown to specifically inhibit tumor growth and the metastasis of ARMS in vitro by acting on the hedgehog pathway. Here we report on a pilot clinical study to evaluate the activity of an ATO-combined chemotherapy approach for the treatment of ARMS patients.MethodsWe designed a therapeutic schedule of an ATO-combined chemotherapy, incorporating comprehensive management according to the Intergroup Rhabdomyosarcoma Study Group protocol. ATO was administered at 0.16 mg/kg per day over 8 h via an IV for 10 days combined with a chemotherapeutic regimen of vincristine, actinomycin, and cyclophosphamide (VAC regimen) on the third day, which was repeated every 21 days. A total of eight cycles of ATO-combined chemotherapy were applied throughout the entire scheme.ResultsA total of three refractory/recurrent and one untreated ARMS patient, three male and one female, with a median age of 5.8 years (range, 5.1 to 12.5 years), were enrolled in the present study. All patients were sensitive to combined chemotherapy with ATO and achieved partial or complete remission during treatment. Except for reversible gastrointestinal reaction and myelosuppression, no other adverse events were observed during the process of treatment.ConclusionsThe combined chemotherapy of ATO and the VAC regimen exhibited beneficial activities against ARMS in pediatrics and was well tolerated, but prospective large-scale clinical trials are warranted to determine the long-term efficacy, optimal courses, and late toxicity in this population.

show abstract

Section: Introductionsupporting

confidence: 61%

Encouraging Early Outcomes of Treatment With Arsenic Trioxide Combined With Chemotherapy for Alveolar Rhabdomyosarcoma in Children: 4 Case Reports

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…SK‐N‐SH human neuroblastoma cell line was selected to allow comparisons on the cytotoxic activity evaluation of hydroxy and oxyprenylated coumarin derivatives studied previously by our group (Kavetsou et al, ). Both SK‐N‐SH and HeLa cells have been widely used to examine the anticancer effect of bioactive agents (Akram et al, ; Dickens et al, ; Goswami et al, ; Park et al, ; Qi et al, ; Swift, Zhang, Trippett, & Narendran, ; Yen et al, ).…”

Section: Resultsmentioning

confidence: 99%

Novel 3‐aryl‐5‐substituted‐coumarin analogues: Synthesis and bioactivity profile

Kavetsou

Katopodi

Argyri

et al. 2020

Drug Development Research

View full text Add to dashboard Cite

Eighteen 3-aryl-5-substituted-coumarins-six 5-acetyloxy-derivatives, six 5-hydroxyderivatives, and six 5-geranyloxy-derivatives-were synthesized, structurally characterized and their antioxidant activity, lipoxygenase inhibitory ability, as well as their cytotoxic activity against human neuroblastoma SK-N-SH and HeLa adenocarcinoma cell lines were evaluated. The 5-acetyloxy-compounds 3a-3f were found to be the best cytotoxic agents among all the compounds studied. The bromo-substituted coumarins 3a and 3b were remarkably active against HeLa cell line showing IC 50 1.8 and 6.1 μM, respectively. Coumarin 5e possessing a geranyloxy-chain on position 5 of the coumarin scaffold presented dual bioactivity, while 5-geranyloxy-coumarin 5f was the most competent soybean lipoxygenase inhibitor of this series (IC 50 10 μM). As shown by in silico docking studies, the studied molecules present allosteric interactions with soybean lipoxygenases.

show abstract

“…Apoptosis Analysis. Apoptosis analysis was conducted with the annexin V-FITC apoptosis assay kit (Abcam, Britain) according to kit instruction, as described by Qi et al [28]. Cells (5 × 10 5 -1 × 10 6 /mL) were suspended in 200 μL BioMed Research International binding buffer; 10 μL annexin V-FITC were added, and cells were incubated in the dark, 4°C for 30 minutes.…”

Section: Luciferase Reporter Assaymentioning

confidence: 99%

“…Cell Cycle Analysis. As described by Qi et al [28], cell cycle analysis was conducted with the Cell Cycle Analysis Kit (BioVision, USA) according to kit instruction. Cells were suspended and washed with PBS three times.…”

Section: Luciferase Reporter Assaymentioning

confidence: 99%

Sirt‐1 Regulates Physiological Process and Exerts Protective Effects against Oxidative Stress

Liu

Xia

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Background. Recent studies suggest a correlation between the reduced Sirt-1 expression with Alzheimer’s diseases (AD) and depression, respectively, suggesting a possible pathogenic role of the altered Sirt-1 expression in neuronal degenerative diseases, such as AD and depression. However, the molecular mechanisms underlying how Sirt-1 reduction impairs neuronal functions remain unknown. Methods. We used the SK-N-SH neuroblastoma cells to study the role of Sirt-1 expression on physiological roles in neuronal cells. Gain of Sirt-1 was achieved by transiently transfecting Sirt-1 expression plasmid. Sirt-1-specific shRNA was used to elucidate the role of Sirt-1 loss of function. CCK-8 (Cell Counting Kit-8) assay and flow cytometry were used to evaluate cell proliferation. Semiquantitative western blotting was used to detect relative protein levels. A further luciferase reporter gene assay was employed to examine the effect of Sirt-1 expression on the transcriptional activity of p53. RT-qPCR was used to determine the mRNA levels of p21, Bax, and Bcl-2, which were the downstream target genes of p53. Results. Sirt-1 suppressed the p53 downstream gene p21 transcription, while shRNA-mediated Sirt-1 knockdown resulted in a significant increase in p21 expression, implying a possibility that Sirt-1 promotes neuron proliferation through suppressing p53 transcriptional activity. The mRNA and protein levels of p53 were not affected by the altered Sirt-1 expression, suggesting that Sirt-1 regulates the transcriptional regulatory activity of p53 rather than p53 expression. Indeed, we further confirmed that Sirt-1 appeared to inhibit p53 transcriptional activity by attenuating its acetylation and resulted in a decrease of p53’s binding to the p21 promoter. Overexpressed Sirt-1 scavenged reactive oxygen species (ROS) production in SK-N-SH with H2O2. Knockdown of Sirt-1 presented opposite effect; the addition of EX527 (Sirt-1 inhibitor) increased ROS accumulation. Conclusions. Oxidative stress induces Sirt-1 in neuron cells, and Sirt-1 promotes proliferation in SK-N-SH cells, which protects them from oxidative stress-induced cell death, potentially via suppressing the transcriptional activity of p53. These results provide a molecular explanation underlying how the reduced Sirt-1 potentially causes the AD and depression-related diseases, supporting the idea that Sirt-1 can possibly be used as a diagnostic biomarker and/or therapeutic drug target for the AD and depression-related diseases.

show abstract

Pre-application of arsenic trioxide may potentiate cytotoxic effects of vinorelbine/docetaxel on neuroblastoma SK-N-SH cells

Cited by 18 publications

References 32 publications

Encouraging Early Outcomes of Treatment With Arsenic Trioxide Combined With Chemotherapy for Alveolar Rhabdomyosarcoma in Children: 4 Case Reports

Encouraging Early Outcomes of Treatment With Arsenic Trioxide Combined With Chemotherapy for Alveolar Rhabdomyosarcoma in Children: 4 Case Reports

Novel 3‐aryl‐5‐substituted‐coumarin analogues: Synthesis and bioactivity profile

Sirt‐1 Regulates Physiological Process and Exerts Protective Effects against Oxidative Stress

Contact Info

Product

Resources

About